CONFIDENTIAL     C1INH (BerinertÂ®) IRI Study in Kidney Transplant  
	


  

CLINICAL STUDY PROTOCOL 
Protocol Title: A Phase I/II, Double-Blind, Placebo-Controlled Study: 
Assessing Safety and Efficacy of Preoperative Renal Allograft Infusions of C1 Inhibitor (BerinertÂ®) (Human) (C1INH) vs. Placebo Administration in Recipi[INVESTIGATOR_22880] a Renal Allograft from Deceased High Risk Donors and its impact on Delayed Graft Function (DGF) and Ischemia/Reperfusion Injury (IRI)  
Test Drug: C1INH (BerinertÂ®) CSL Behring Inc.  
Sponsorâ€™s Name [CONTACT_1781]: Stanley Jordan, MD 
[ADDRESS_1019044]  Los Angeles, CA [ZIP_CODE]  
Sponsorâ€™s Telephone Number: 
 
Sponsorâ€™s FAX: [PHONE_2497] 
 
[PHONE_2498]  
 Collaborator:   Study Number and Protocol 
Version Number/Date:  
OneLegacy  IRB#469. FDA IND [ZIP_CODE]. Version 5.0, January 26, 2022  
 Incorporate Amendment:  Development Phase:   
PI:  
  
 [CONTACT_7609] I/II    Stanley C. Jordan, M.D., FASN 
Director, Nephrology & Transplant Immunology 
Department of Medicine & Pediatrics Cedars-Sinai Medical Center [ADDRESS_1019045]  L.A., CA. [ZIP_CODE] Telephone: [PHONE_2497] Fax: [PHONE_2498] e-mail: [EMAIL_2153]  
 
 Ashley A. Vo, Pharm.D Director, Transplant Immunotherapy Program 
Cedars-Sinai Medical Center 
[ADDRESS_1019046]  L.A., CA. [ZIP_CODE] Telephone: [PHONE_11220] Fax: [PHONE_2498] e-mail: [EMAIL_10351]  
  
   
CONFIDENTIAL     C1INH (BerinertÂ®) IRI Study in Kidney Transplant  
	


 
       
 
   
Clinical Trial Coordinator: Noriko Ammerman, Pharm.D 
Research Pharmacist Transplant Immunotherapy Program Cedars-Sinai Medical Center [ADDRESS_1019047]  L.A., CA. [ZIP_CODE] Telephone: [PHONE_11221] Fax: [PHONE_2498] e-mail: [EMAIL_14241] 
 
      
 
 
  
CONFIDENTIAL     C1INH (BerinertÂ®) IRI Study in Kidney Transplant  
	


 
Table of Contents 
1. Introduction .................................................. 7 
2. Hypothesis ................................................... 16 
2.1 Study Objectives ............................................. 13 
2.2  Study Synopsis.......................................... 13 
3. Investigator(s) And Other Study Participants ................. 20 
4. Investigational Plan ......................................... 21 
4.1 Study Design And Plan ........................................ 21 
4.1.1 Study Drug Administration Timing ............................. 21 
4.2 Selection Of Study Population ................................ 22 
4.2.1 Inclusion Criteria ........................................... 23 
4.2.2 Exclusion Criteria ........................................... 24 
4.3 Removal Of Subjects From Study ............................... 24 
4.4 Premature Termination Of Study/Closure Of Center ............. [ADDRESS_1019048](s) ....................... 26 
4.5.3 Method Of Assigning Subjects To Treatment Groups ............. 27 
4.5.4 Selection Of Doses In The Study .............................. 27 
[IP_ADDRESS] C1INH Dosing ............................................ 27 
[IP_ADDRESS] Placebo Dosing .......................................... 27 
4.5.5 Immunosuppression ............................................ 27 
[IP_ADDRESS] Induction Antibody Therapy .............................. 27 [IP_ADDRESS] Maintenance Immunosuppression ........................... 28 [IP_ADDRESS].1 Calcinurine Inhibitors .................................. 28 [IP_ADDRESS].2 Mycophenolate Mofetil ................................... 28 [IP_ADDRESS].[ADDRESS_1019049] ................ 29 
4.5.8 Blinding ..................................................... 29 
4.5.9 Treatment Compliance ......................................... 30 
4.6 Study Variables .............................................. 30 
4.6.1 Efficacy Variables ........................................... 30 
[IP_ADDRESS] Primary Efficacy Endpoints .............................. 30 
[IP_ADDRESS] Secondary Efficacy Endpoints ............................ 30 4.6.2 Safety Variables ............................................. 31 
[IP_ADDRESS] Adverse Drug Reactions .................................. 32 [IP_ADDRESS] Assessment of Risk for Thrombotic Events with  C1INH 
Administration ............................................... 32 
[IP_ADDRESS] Evidence of a Thrombotic Effect of C1INH Administration when 
Given in Supraphysiologic Dosages to Humans ............. 32 
[IP_ADDRESS] Evidence of a Thrombotic Effect of C1INH Administration when 
Given in Supraphysiologic Dosages to Animals ............ 33 
[IP_ADDRESS] Therapy Stoppi[INVESTIGATOR_108939] ................................. 34 [IP_ADDRESS] Primary Saftey Endpoints ................................ 34 
[IP_ADDRESS] Secondary Safety Endpoints .............................. 34 
CONFIDENTIAL     C1INH (BerinertÂ®) IRI Study in Kidney Transplant  
	


4.6.3      Assessment Periods ....................................... 34 
[IP_ADDRESS] Screening Procedure ..................................... 34 [IP_ADDRESS] Day 0 - Day of Transplantation .......................... 35 [IP_ADDRESS] Day 1-7 Assessments measured daily through day 7 or until 
discharge ............................................... 36 
[IP_ADDRESS] Day 30 Â± 5 days ......................................... 37 [IP_ADDRESS] Days 90, 180 Â± 15 days .................................. 37 4.6.4      Observations And Measurements ............................ 37 
[IP_ADDRESS] Physical Examination .................................... 37 
[IP_ADDRESS] Vital Signs ............................................. 38 [IP_ADDRESS] Serum Creatinine ........................................ 38 [IP_ADDRESS] Calculated Creatinine Clearance / Calculated GFR ........ 38 [IP_ADDRESS] Urine Output ............................................ 38 [IP_ADDRESS] PT, PTT and INR Tests ................................... 38 [IP_ADDRESS] Hematology and Chemistry Profile ........................ 38 [IP_ADDRESS] ECG Testing ............................................. 39 [IP_ADDRESS] ACR Assessment .......................................... 39 [IP_ADDRESS] Rate and Duration of Dialysis ........................... 39  4.7 Data Quality ................................................. 39 
4.8 Documentation ................................................ 39 
5. Ethical And Legal Aspects .................................... 40 
5.1 Ethics Committee (EC) Or Institutional Review Board (IRB) .... [ADDRESS_1019050] Of The Study ................................. 40 
5.3 Regulatory Authority Approvals/Authorizations ................ [ADDRESS_1019051] Information And Consent .............................. 41 
5.5 Confidentiality .............................................. 41 
6. Statistical Methods And Determination Of Sample Size ......... 41 
6.1 Statistical And Analytical Plans ............................. 41 
6.2 Determination of Sample Size ................................. 41 
7. Adverse Events (AEs) ......................................... 44 
7.1  Adverse Event (AE) Monitoring ................................ 44 
7.2 Adverse Event (AE) Definitions ............................... 44 
7.2.1   Adverse Events (AEs) ....................................... 44 
7.2.2   Serious Adverse Event (SAE) ................................ 44 
7.2.3   Unexpected Adverse Event (AE) .............................. [ADDRESS_1019052] ..... 46 
7.2.5 Severity Of The Adverse Event (AE) ........................... 47 
7.2.6 Adverse Event (AE) Documentation ............................. 47 
7.3 Reporting of Serious Adverse Events (SAEs) or Pregnancy ...... 48 
8.0 References ................................................... 49 
9. Appendices ................................................... 54 
9.1 Calculation of GFR ........................................... 80 
  
CONFIDENTIAL     C1INH (BerinertÂ®) IRI Study in Kidney Transplant  
	


Glossary and Abbreviations 
 
AE Adverse Event CRF Case Report Form (either paper or electronic) EC Ethical Committee GCP Good Clinical Practice IRB Institutional Review Board MRR Medical Research Report 
SAE Serious Adverse Event 
SOC Standard of Care DGF Delayed Graft Function EGF Early Graft Function CVA Cerebral Vascular Accident DCD Donation after Cardiac Death ECD Extended Criteria Donor GFR Glomerular Filtration Rate UNOS United Network for Organ Sharing SCD Standard Criteria Donor OPTN National Organ Procurement and Transplantation Network ACR Acute Cellular Rejection C1INH C1 inhibitor (Berinert
Â®) 
CMV Cytomegalovirus 
IRI Ischemia-Reperfusion Injury USRDS The [LOCATION_002] Renal Data System WFI Water for Injection 
   
       
 
   
  
CONFIDENTIAL     C1INH (BerinertÂ®) IRI Study in Kidney Transplant  
	


	1.0 Introduction 
Delayed graft function (DGF), defined as the need for dialysis in the first 
week after kidney transplant, is estimated to occur in over 20% of deceased donor kidney transplants (1).  Its development is associated with an increased risk of rejection, poorer long-term kidney allograft function, and lower patient and graft survival (2,3).  This association is modified by [CONTACT_745043], as indicated by [CONTACT_745044]-dependence after transplant, where longer periods of dialysis-dependence are associated with 
progressively higher risks  of rejection and graft failure (4).  Not 
surprisingly, kidneys at higher risk for DGF are more likely to be discarded in the [LOCATION_002] despi[INVESTIGATOR_45478]-documented shortage in donor organ supply (5,6). 
 
The predominant mechanism of DGF is ischemia-reperfusion injury.  This is 
marked by [CONTACT_745045]-independent inflammatory response, characterized by [CONTACT_745046]-inflammatory cells early after ischemic injury (7).  Additionally, the complement cascade can be activated in response to ischemia-induced membrane changes (8).  Although the alternative pathway has historically been thought to play the major role in ischemia-reperfusion injury, evidence suggests that the classical and mannose binding lectin (MBL) pathways are also important (9,10).  Damage-associated molecular 
patterns (DAMPs), polysaccharides, and intracellular antigens exposed during 
ischemic injury can activate both the classical and MBL pathways (11).  C4-deficient mice, who cannot activate the classical pathway C3 convertase (C2aC4b), were less susceptible to ischemia-induced injury compared to wild-type mice and antibodies against mannan-binding lectin-associated serine protease (MASP)-[ADDRESS_1019053] and myocardium (11,12).  Recent data from an animal model of heart transplant ischemia-reperfusion injury demonstrated that ischemia-reperfusion injury was largely prevented in animals that were genetic knockouts for the MBL collectin-11 but not for Factor B (alternative pathway) knockouts (10).  In addition, wild-type mice treated with C1 esterase inhibitor were protected from ischemia-reperfusion injury, similar to collectin-11 (-/-). Thus, mounting experimental evidence suggests 
blockade of the classical and MBL complement pathways is a potentially 
attractive approach for prevention or mitigation of DGF caused by [CONTACT_114273]-reperfusion injury. Of interest is recent data linking IRI/DGF to induction of B-cell injury and DSA generation post-transplant. This is discussed below: 
 Evidence for B-cell Activation in Allografts Experiencing IRI/DGF Cippa et al (13) in an elegant article published in Nature demonstrated a 
causal relationship between IRI/DGF and subsequent B-cell activation in the allografts. This clearly differed from allografts not experiencing IRI/DGF as no B-cell signals were demonstrated on protocol biopsies. The authors showed that production of DSAs post-transplant was a late event reflecting 
irreversible organ damage due to IRI/DGF. The authors conclude that their 
findings point to new opportunities for early diagnosis and novel therapeutic interventions that could prevent or alter IRI/DGF induced immune 
CONFIDENTIAL     C1INH (BerinertÂ®) IRI Study in Kidney Transplant  
	


activation events in the allograft. Here, early ischemic events incite 
innate immune systems (complement activation) that ultimately leads to chronic injury and activation of B-cells through exposure to cryptic antigens resulting in DSAs. Prevention of this early IRI/DGF damage should limit immune activation of B-cells and DSA inducted injury later post-transplant. See Figures 1A and 1B for the data presented in this manuscript.  
 
Fig. 1A 
Chronic kidney injury and B cell immunity in human allografts. Heatmap 
showing the gene expression correlation of the [ADDRESS_1019054] variably expressed genes 
across kidney biopsies collected at 3 and 12 months after transplantation (N =80). 
The names of the genes included in the cluster in the bottom right corner are 
shown. b, c RPKM values of MS4A1 (CD20) and IGKC over time in human kidney allograft biopsies. BL: baseline. N= 39â€“[ADDRESS_1019055], ****P < 0.0001, **P < 0.01, *P < 0.05. d Semi-quantitative evaluation of immune cell infiltrates in the kidney at different time points after 
transplantation as determined by [CONTACT_745047]. N = 39â€“[ADDRESS_1019056], **P < 0.01. e Cluster analysis based on the expression of B cell-associated genes including kidney biopsies collected at 12 months after transplantation (N= 39). Patients classified in the CKI group are indicated on the left. f t-SNE analysis on RNAseq data from 
kidney biopsies collected 12 months after transplantation defining the 
classification of patients in the CKI group. The boundary was determined by [CONTACT_745048] t-SNE plot. N = 39. g RPKM values of COL1A1 and MMP2 shown as examples of genes differentially expressed in CKI and non-CKI. Mean value and standard error (SE) are shown. Mannâ€“Whitney test, ****P < 0.0001. (13) 
 
Data presented in this manuscript also demonstrated increased allo- and 
auto-antibody production in microarray analysis of blood from patients experiencing IRI/DGF post-transplant.  

CONFIDENTIAL     C1INH (BerinertÂ®) IRI Study in Kidney Transplant  
	


 
Figure 1B : Volcano plot comparison of signal-to-noise ratio in IgG reactivity in 
plasma samples collected 16â€“18 months after IRI (n = 6) and in age-matched controls 
(n= 6) on microarray of autoantigens, with indication of log2-fold change on the x-axis (>0 indicates higher in IRI) and significance level. (13) 
 
 
1.1Criteria for Defining IRI/DGF in Human Kidney Transplants 
Historically DGF has been defined as the requirement for dialysis during the 
first week after renal transplantation, however the postoperative requirement of hemodialysis or peritoneal dialysis is not standardized and the decision to dialyze varies from center to center and among consultants (14). Efforts have been made to scientifically quantify DGF in a more stringent manner with various alternative definitions of DGF including; (14) the number of days to achieve a creatinine clearance of >10 mL/min, 
calculated by [CONTACT_540417]-Cockroft formula (15) a serum creatinine level of >3 
mg/dL on the fifth day post-transplant (16) the need for dialysis within 72 hours after transplantation  (17) serum creatinine level changes, including an increase, remaining unchanged, or decreasing by [CONTACT_21316] 10% per day immediately after surgery during three consecutive days for >1 week (18) a rising serum creatinine level above that before surgery, or urine output of <300 mL within 6 hours of transplantation, despi[INVESTIGATOR_540377] (19) urine output of <[ADDRESS_1019057] 24 hours or a decrease in serum creatinine of <20-30% reflected in a poor glomerular filtration rate (GFR) (20) and calculating the creatinine reduction ratio on day two following surgery  (21). However, despi[INVESTIGATOR_745003], the conventional definition of â€œrequirement for dialysis in the first week post-
transplantâ€ remains the most utilized and published definition for DGF, with 
â€œneed for dialysisâ€ being easily measured and clinically relevant. However, recent data from the FDA indicate that more relevant end points for clinical trials of agents aimed at reducing IRI/DGF would be need for dialysis in the first month post-transplant and eGFR at 1year  (https://www.fda.gov/media/103928/download . 
 
1.2 The Kidney Donor Profile Index (KDPI) 
Key to the success of any study aimed at evaluating efficacy against IRI/DGF 
is the reasonable stratification of risk for said event. In recent years this has been codified using the KDPI [INVESTIGATOR_632596]. The Kidney Donor Profile Index (KDPI) is a numerical measure that combines ten donor factors, including clinical parameters and demographics, to summarize into a single number the 

CONFIDENTIAL     C1INH (BerinertÂ®) IRI Study in Kidney Transplant  
	


quality of deceased donor kidneys relative to other recovered kidneys. The 
KDPI [INVESTIGATOR_745004] (KDRI) for a deceased donor.  
Kidneys from a donor with a KDPI [CONTACT_4007] 90%, for example, have a KDRI (which 
indicates relative risk of graft failure) greater than 90% of recovered kidneys. The KDPI [INVESTIGATOR_745005] a mappi[INVESTIGATOR_745006] a relative risk scale to a cumulative percentage scale. The reference population used for this mappi[INVESTIGATOR_745007] a kidney recovered 
for the purpose of transplantation in the prior calendar year. Lower KDPI 
[INVESTIGATOR_745008]. This is shown in  figure 2 below: 
 
 
 
Figure 2 : This figure shows the outcomes of kidney transplants performed 2007-[ADDRESS_1019058] scores (86-100%) 
experienced the worst outcomes over time. This would suggest that kidneys donated from patients with high risk for IRI/DGF are unlikely to provide long-term benefits to patients, thus may be discarded. 
 
 
1.3 Complement as a Mediator of Ischemia Reperfusion Injury (IRI) 
 
The complement system in humans exists as a system of recognition molecules, proteolytic enzymes and receptors for activated complement components that are responsible for host defense. The complement system can be activated in at least 3 separate ways; first, the classical pathway which depends on antibody binding to antigen targets and binding complement components (i.e. C1q) to ultimately activate C3 and initiate terminal complement component activation of C5b-C9 (see figure 3). Binding of lectins (i.e. mannose binding lectin and mannose binding lectin serine protease (MBLSP) activate 
the C3 convertase without activation of C1->4->2 (C3 convertase). In 
addition, the alternative pathway is activated by [CONTACT_745049] H
2O or 
activating surfaces. The deposition of complement on bacteria or sites of injury signal initiation of an inflammatory response and tags complement bound targets for elimination through apoptosis or phagocytosis by [CONTACT_179968]. The complement system also contains a number of receptors that 

CONFIDENTIAL     C1INH (BerinertÂ®) IRI Study in Kidney Transplant  
	


modify or abate complement-mediated inflammation. Complement also exists in 
two distinct compartments (central and local). The central compartment of complement is produced in the liver and is responsible for all circulating complement factors. The peripheral compartment included complement generated locally in organs such as the CNS and kidneys (22) Activation of complement in the peripheral compartments appears to be regulated primarily by [CONTACT_540420]. Figure 2 below describes the importance of complement activation in initiation of renal tubular cell (RTC) injury with reference to induction by 
[CONTACT_540420]. Briefly, IRI stimulates C3 production in the RTCs that is subsequently 
cleaved by [CONTACT_540421]/MBLSP or alternative pathway (22). C3b generated then activates C5 to C5a and C5b. C5b forms the C5b-C9MAC which induces cell death and cytokine (IL-6) release. C5a interacts with the C5aR to induce apoptosis and cell death. Data from have also shown that kidneys from C3 deficient mice are resistant to IRI. Other investigators have also shown that expression of C3 and other complement components in human donor kidneys before transplantation had a negative impact on graft outcome at 2-3 years (23). Thus there is significant support for a role of complement activation in inducing RTC injury and ultimately DGF and it would be reasonable to assume that administration of complement inhibitors would be of potential benefit in prevention or amelioration of RTC injury and possibly improve outcomes in kidneys at high risk for development of DGF.  
 
As previously mentioned, this field has evolved considerably in the past 2-3 years. Recent data from a small consortium trial examined the utility of eculizumab (anti-C5) for prevention of IRI/DGF in a protocol similar to the one we previously reported with C1INH.(24)  Here, the investigators showed no benefit on prevention of IRI/DGF and no long term benefit in improving eGFR in treated v. placebo patients. This would seem to challenge the findings of our larger study with C1INH v. placebo where significant benefits in reducing IRI/DGF were seen early that translated into long-term benefits in graft survival and renal function (24, 25). The differences seen in the two trials may be explained by [CONTACT_745050]. Data summarizing this information is shown below. Briefly, data from Sacks et al (26) (27) have recently demonstrated that the lectin 
pathway of complement activation is critical to IRI/DGF injury in animal 
models. This finding implicated IRI induced expression of fucose on renal tubular cells that directly binds to the MASP collectin-11. The binding of this serine protease activates complement through the lectin pathway resulting in C5b-C9MAC and C5a induced ischemic injury to tubules. This is shown in Figure 4 below. These authors also found that collectin-11 was critical to the induction of interstitial fibrosis and tubular atrophy in experimental models. The conundrum regarding the differences in complement inhibitors used in the two studies discussed above may be resolved by a study reported by (10)  Using a heart transplant model of IRI/DGF injury, these investigators examined the role of complement using specific knock-out mice. Here, Factor B (-/-) animals showed no benefit in prevention of 
IRI/DGF suggesting that the omission of the alternative complement 
activating pathway had no impact on prevention of IRI/DGF (10). This is important since the alternative pathway is best inhibited by [CONTACT_151305]. In addition, the investigators performed similar experiments using collectin-11 (-/-) mice. Here dramatic differences were seen with knock-out of the collectin-11 gene expression resulting in a significant inhibition of 
CONFIDENTIAL     C1INH (BerinertÂ®) IRI Study in Kidney Transplant  
	


IRI/DGF injury to allografts. This data would tend to confirm the importance 
of the interactions of collectin-[ADDRESS_1019059] for IR injury. Further support for this contention was shown when the investigators used C1INH treatment in this model. Here, results recapi[INVESTIGATOR_745009]-11 (-/-) experiments suggesting that C1INH treatment may have unique benefits in preventing IRI/DGF injury to allografts (10). The complement activation pathways and their roles in IRI/DGF are shown in Figure [ADDRESS_1019060] significance in 
prevention of IRI/DGF, specifically, the role in inhibiting collectin-11 binding to fucose moieties on renal tubular cells.   
 
Figure 3: 
This figure shows the impact of ischemic injury on RTCs. Ischemia 
induces complement activation through the lectin pathway (MASP-> Collectin-11) 
binding to fucose moieties expressed on injured tubular epi[INVESTIGATOR_1663]. Complement injury proceeds with damage to RTC epi[INVESTIGATOR_745010]-term implications.   
 

 #%
  
 #%
!$
)
)' ,&*
,'*
++ + &'!!%
	
(*

!  
 !% !!
 "  ! 

 #%

- -    	 '! !% !!

 
	

	




	

	


!!#
'
 '	
 (
(
(%*
%)
	




(

(

"
!



!!

(

  ))
!
!,
CONFIDENTIAL     C1INH (BerinertÂ®) IRI Study in Kidney Transplant  
	


 
 
 
Figure [ADDRESS_1019061]. These 
findings distinguish the mechanisms of action of anti-C5 v. C1INH and are supported 
by [CONTACT_745051]. who demonstrated that the beneficial effects of collectin-11 (-/-) could be recapi[INVESTIGATOR_745011] C1INH treatment. 
 
 
1.4 Evidence for C1INH Prevention of IRI in Animal Models 
Although limited, there are recent investigations which show dramatic 
results in prevention of IRI after C1INH treatment. (28) investigated the ability of recombinant C1INH (rC1INH) to alter tissue injury in a porcine model of controlled hemorrhage. In this model, the administration of 100U/kg or 250U/kg rC1INH significantly reduced IRI injury to kidneys, lungs, intestine and liver. The animals treated with 250U/kg also showed 
significant reductions in TNF- Î± levels and severity of metabolic acidosis. 
The significant beneficial effects of rC1INH administration were found to be related to the ability of C1INH to reduce IRI induced complement activation in tissue. All treated animals also showed reduced immune cell infiltration and cytokine production. The authors felt that the use of rC1INH would have significant benefits in patients with hemorrhagic shock in prevention of IRI and organ failure (29). In a comprehensive analysis of rC1INH use in an IRI model of kidney injury in the swine model found that IRI was associated with significant C3 activation, primarily through the MBL/MBLSP-[ADDRESS_1019062]. The infusion of rC1INH led to significant reductions in peritubular capi[INVESTIGATOR_1396] C4d deposition, and C5b-C9MAC. Complement inhibition with rC1INH also reduced the numbers of infiltrating CD163+, CD4+ and CD8+ T-cells. Animals 
""
#&(
 
#
#&(
	$ '
/
/!+" 2)0
2+0
11 1
(#(#	$!(-.

###%#

$(##%#
#	#)	"+ !$"	$!(

,0
!
$##!
#!	"	$!(#$$!"
#%#" #!$
#

#&(

3 3 /"#!"	#!*
##	#!		#$ $!"
/	
/	


!!#
'
 ' 	
 (
(
(%*
%)
	




(

(

"
!



!!

(

#,//
$"/	
$!3
CONFIDENTIAL     C1INH (BerinertÂ®) IRI Study in Kidney Transplant  
	


treated with rC1INH had significantly less RTC injury and renal damage. The 
authors conclude that the use of C1INH may represent a novel therapeutic approach in the prevention of DGF that would have particular relevance to kidney transplantation. Data from animal models of stroke induced by [CONTACT_745052] (MCA) occlusion showed that significant benefits in reducing infarct size were obtained with C1INH given at 20U/kg. Here, C1INH was shown to bind to microvasculature in the brains of animal who showed protection, presumable through prevention of IRI induced complement activation. (30), 
C1-inhibitor protects from brain ischemia-reperfusion injury by [CONTACT_745053]-inflammatory and antithrombotic mechanisms. 

Figure 5 :  
Immunohistochemistry for human C1-INHin an infarcted (left) and healthy 
contralateral (right)rat hemisphere [ADDRESS_1019063] is related to C1INH inhibition of complement activation on the capi[INVESTIGATOR_745012]. 
 
 1.5 Evidence for Efficacy of C1INH in Preventing IRI/DGF in Human Kidney 
Transplant Recipi[INVESTIGATOR_840] 
C1 esterase inhibitor was approved by [CONTACT_745054] [ADDRESS_1019064] of complement inhibition on short- and long-term kidney function among allografts with ischemia-reperfusion injury.  Our group recently reported twelve-month outcomes of a double-blind, randomized, placebo-controlled study investigating the safety and efficacy of C1 esterase inhibitor among deceased donor kidney transplant recipi[INVESTIGATOR_745013]-risk for DGF (25).  Salient findings from this study were a shorter duration of DGF and higher 
estimated glomerular filtration rate (eGFR) at twelve months among patients 
treated with C1 esterase inhibitor compared to placebo. From our initial report we showed that C1INH was associated with a ~50% reduction in need for dialysis in the first month post-transplant in high risk patients and a clinically significant improvement in eGFR at 1 year. This is shown in 

CONFIDENTIAL     C1INH (BerinertÂ®) IRI Study in Kidney Transplant  
	


figure 6 below. For more details please see the referenced manuscript that 
is attached as an appendix.  
 
 
Figure 6 : This figure demonstrates that giving C1INH 50U/kg at time of transplant 
and @[ADDRESS_1019065]-transplant and a significant improvement 
in eGFR at 1 year compared to placebo. The at risk population was balanced for risk factors associated with IRI/DGF being enriched for the risk. This data would suggest that prevention of early IRI/DGF has long-term implications for improving 
kidney function. 
 
 
We have subsequently assessed the long-term (3.5 year) outcomes of patients 
treated with C1INH v. placebo and saw that the results for improvements in 
eGFR have been sustained over the 3.5 year follow up.(31)This is also associated with an improved graft survival in the C1INH group and is shown in figures 7B and 8 below.  Briefly, in figure7A, we show that in the C1INH 
group, the eGFR is maintained at +0.5 cc/min/1.73m
2/year for 3.5 years. 
However, the placebo group showed a decline of - 4.1cc/min/1.73m2/year 
(p=0.03). We also saw that the graft survival was significantly decreased in the patients receiving placebo (p=0.007), again suggesting that prevention of early IRI/DGF is associated with a beneficial long-term survival and function of the kidney allografts. Although not statistically significant, there was a numerically important reduction in DSA generation post-transplant in the C1INH treated patients. This may be related to benefits in reducing ischemia-related activation of B-cells with subsequent DSA generation.(31) Time Since Transplantation (days)0 2 4 6 8 1 01 21 41 61 82 02 22 42 62 83 0Freedom From Dialysis Probability
0.0 0.2 0.4 0.6 0.8 1.0
34151515131313 [ZIP_CODE] 55 431 C1INH
[PHONE_15553] 1615 128888 77 66 555 44 33333333 22 PlaceboC1INH
Placebo
N at Risk/RJÃ¯ rank p=0.136
0255075p=0.102 p=0.017 p=0.043 p=0.006
C1INH PlaceboeGFR (mL/min/1.73m2)
7LPHSRVWÃ¯ Transplantation (days)0 100 200 300 365
CONFIDENTIAL     C1INH (BerinertÂ®) IRI Study in Kidney Transplant  
	


 
 
Figure 7A : Data from our randomized placebo-controlled trial show that at 3.5 
years C1INH treatment at transplant results in a significant improvement in eGFR 
compared to placebo treatment. The slope of eGFR was -4.1 cc/min/1.73m2/year in placebo v. +0.5cc/min/1.73m2/year in C1INH p=0.03. 
 
 
 
Figure 7B : This figure shows the patient and graft survival at 3.[ADDRESS_1019066]-transplant that were not related to C1INH administration. 
 
 !	


 





	




	




	
# '!  &"!

 
	
$"%#$ &"!


	 


%	 #

 $!

"

  &#'   &#'
	  
   &#'!%	 

CONFIDENTIAL     C1INH (BerinertÂ®) IRI Study in Kidney Transplant  
	


	A summary of the data generated from our 3.5 year follow up study is shown 
below and will be published soon in the Clinical Journal of the American 
Society of Nephrology . 
 
Figure 8 : A summary of the data from our 3.5 year follow-up of C1INH treatment of 
high-risk kidney allograft recipi[INVESTIGATOR_745014]. Briefly the study was a placebo-
controlled, blinded trial of C1INH v. placebo administered to a total of 70 (35 placebo & 35 C1INH) patients at risk for IRI/DGF. Data at 3.5 years show that C1INH treatment was associated with a significant improvement in eGFR and reduction in 
graft loss compared to placebo treated patients. 
 

2.[ADDRESS_1019067]-transplant and, more importantly, significant improvements in renal function and graft survival 3.5 years after intravenous C1INH infusion,  we hypothesize that the use of C1INH perfused into the kidney prior to transplant in patients receiving deceased donor (DD) kidney transplants with high risk for DGF (KDPI >80)  will also show significant reductions in DGF and improved outcomes post-transplant compared with patients receiving KDPI >80 DD transplants receiving placebo treatment.  
 
2.1 Study Objectives In this study, we propose to investigate the application of pre-operative 
doses of C1INH (BerinertÂ®)administered by [CONTACT_745055]. 
Methods and Cohort OutcomesWhat are the 3-year outcomes of an RCT assessing the safety 
and efficacy of C1 esterase inhibitor for prevention of DGF?
Edmund Huang, Ashley Vo, Jua Choi, et al. Three-Year Outcomes of a Randomized, Double-
Blind, Placebo-Controlled Study Assessing Safety  and Efficacy of C1 Esterase Inhibitor for 
Prevention of Delayed Graft Function in Deceased Donor Kidney Transplant Recipi[INVESTIGATOR_840]. 
CJASN doi: 10. 2215/CJN.04840419. Visual Abstract by [CONTACT_745056], MDConclusion Treatment of patients at risk for ischemia-
reperfusion injury and delayed graft function with C1 esterase 
inhibitor was associated with lower incidence of graft failure.
Follow-up of 3.[ADDRESS_1019068]-hoc analysis of a
phase I/II RCT
70 recipi[INVESTIGATOR_745015]1 esterase 
inhibitor 50 U/kg
PlaceboN=35
N=35eGFR slope
ml/min/1.73m2eGFR at 3.5y 
ml/min/1.73m2Cumulative incidence 
of graft failuresDeaths3
0 21%3% 0.5 
(-4, 5)
-4 
(-8, -0.1)56 
(42, 70)
35 
(21, 48)
CONFIDENTIAL     C1INH (BerinertÂ®) IRI Study in Kidney Transplant  
	



placebo, 1-2 hours prior to implantation, in adult subjects receiving a 
deceased donor renal allograft considered at high-risk for IRI and DGF (KDPI>80). We hypothesize that C1INH treated patients will demonstrate improved function of the kidney allograft compared to placebo, with equivalence in safety. The primary objectives of this study are, using a 
double blinded, placebo controlled format, we will :  
1.Evaluate and compare the safety of C1INH (500U/kidney) administered 
pre-transplant by [CONTACT_745057][INVESTIGATOR_745016] >80 kidney allografts from high risk deceased donors.  
The secondary objectives are to:  
1.Determine if BerinertÂ® (C1INH) study dose 500U/kidney results in 
benefits of reducing need for dialysis in the [ADDRESS_1019069]-
transplant. 
2.Determine if BerinertÂ® (C1INH) study dose 500U/kidney results in 
benefits in improving long-term patient & graft survival and results in improved kidney function at 1 year compared to placebo infusions in the kidney. 
 2.2 Study Synopsis 
TITLE A Phase I/II, Double-Blind, Placebo-Controlled Study: 
Assessing Safety and Efficacy of Intraoperative Intrarenal Infused  C1 Inhibitor(Human) (C1INH)vs. 
Placebo in Recipi[INVESTIGATOR_22880] a Kidney Allograft from Deceased 
High Risk Donor (KDPI >80)and its impact on Risk for  Delayed Graft Function (DGF)  
INVESTIGATIONAL 
AGENT C1INH (BerinertÂ® [human][C1INH]) 
HYPOTHESIS Pre-operative, infusion of C1INH into the renal allograft 
artery 1-[ADDRESS_1019070] on graft 
survival. Poor early graft function and DGF contributes to decreased short- and long-term patient and graft survival, increased incidence of acute rejection, prolonged hospi[INVESTIGATOR_059], and higher costs of 
transplantation.  Although multiple factors contribute to 
the impaired graft function, ischemia-reperfusion injury (IRI) is the underlying pathophysiology leading to poor early graft function and DGF.  A >35% incidence of DGF has remained constant over time despi[INVESTIGATOR_745017].  This may be due to increased use of kidneys from â€œextended-criteriaâ€ and/or non-heart-beating donors, where even greater rates (>60%) of DGF have been reported.  
CONFIDENTIAL     C1INH (BerinertÂ®) IRI Study in Kidney Transplant  
	


 
More than 94,653 people are currently waiting for a kidney transplant in the [LOCATION_002] (UNOS.org 9/30/2019).  Of the 19,360 kidney transplants performed in the US in 2018, 20% were from DCD donors and 9% from donors of KDPI>85.    The USRDS reports that more than 50% of patients on the waiting list are willing to accept a kidney from an expanded-criteria donor (KDPI >85). This study will seek to expand the use of high KDPI [INVESTIGATOR_745018] 
C1INH treatment.   
NUMBER OF PATIENTS AND CENTERS 40 patients will be enrolled into the study (20 C1INH and 
20 Placebo). The study will be performed at Cedars-Sinai Medical Center. In 2018, we transplanted 38 kidneys into patients with KDPI > 85%. We anticipate the rate of offers from OneLegacy will continue at that rate. However, we would propose that 18-20 months will be required to complete study entry given the vagaries of acceptable offers and willingness of individual patients to participate in clinical trials.  
INVESTIGATOR / CLINICAL TRIAL LOCATION Stanley C. Jordan, M.D. 
Cedars-Sinai Medical Center 
STUDY OBJECTIVES â€¢To evaluate and compare the safety of BerinertÂ® (C1INH) 
500U/kidney in recipi[INVESTIGATOR_22880] a kidney allograft from high KDPI [INVESTIGATOR_745019] (KDPI >80) receiving kidneys infused with BerinertÂ® (C1INH) 500U/kidney or placebo pre-operatively.   
â€¢To evaluate early kidney function in recipi[INVESTIGATOR_22880] a 
kidney allograft from a high KDPI [INVESTIGATOR_745020]-renal administration of BerinertÂ® (C1INH) pre-operatively compared to placebo. 
 STUDY DESIGN  
Patients who fulfill all I/E criteria will be eligible to be enrolled into Study I Study Group (40 patients):   
      Treatment Arm  I â€“ KDPI >80 kidneys will be infused 
with one intrarenal dose of 500U of BerinertÂ® in OR prior to implantation into the recipi[INVESTIGATOR_841]. 
    Control Arm â€“ KDPI >80 kidneys will be administered 
one intrarenal dose of normal saline (NS) in the OR in a volume identical to the volume of the dose of BerinertÂ® before implantation of kidney into the patient.  
   Drug v. placebo administration will be randomized 1:1. 
Drug preparation and randomization will be carried out in a blinded fashion by [CONTACT_44499].   
STUDY POPULATION 
 Inclusion Criteria: 
CONFIDENTIAL     C1INH (BerinertÂ®) IRI Study in Kidney Transplant  
	


1)Adult men or women (18-77 years of age) who are on 
chronic dialysis therapy and acceptable candidates for receipt of a kidney transplant. 
2)Recipi[INVESTIGATOR_745021] (A2 to B offers allowable)  
3)Understand and sign a written inform consent prior 
to any study specific procedure 
4). AND one of the below criteria:  a)Recipi[INVESTIGATOR_745022] >80 donors 
b)Recipi[INVESTIGATOR_745023] 
c)Recipi[INVESTIGATOR_745024] > 24 hours 
d)Recipi[INVESTIGATOR_745025]/CRRT 
prior to death/procurement  
e)Recipi[INVESTIGATOR_745026] â‰¥3.0 mg/dL  
f)Patient risk a total risk index score of â‰¥3 based on 
the following: 
	

"		
 


 
	! 
"!

!#




	
 ! 
 !#



	
 
	







	


 
	

	

	
 

#


	##

"


 
Exclusion Criteria:  
1)Patients with a known pro-thrombotic disorder. (eg. 
Factor V Leiden) 
2)Patients with a history of thrombosis or 
hypercoagulable state, excluding access clotting. 
3)Patients with a history of administration of C1INH 
containing products or recombinant C1INH within 15 days prior to study entry. 
4)Patients with a known hypersensitivity to treatment 
with C1INH. 
5)Patients with an abnormal coagulation function. (INR 
>2, PTT> 50, PLT<60,000) who are not on anti-
coagulation. 
CONFIDENTIAL     C1INH (BerinertÂ®) IRI Study in Kidney Transplant  
	


6)Patients with known active presence of malignancies. 
7)Patients who are PCR positive for Hep B, Hep C, or 
HIV. 
8)Recipi[INVESTIGATOR_540388]-emptive kidney transplantation 
(unless baseline SCr is â‰¥4 mg/dL, making minimal 
urine output) 
9)All zero mismatch kidneys. 
10)Recipi[INVESTIGATOR_540389]-organ transplants. (kidney 
and any other organ) 
11)Recipi[INVESTIGATOR_745027]  
12)Recipi[INVESTIGATOR_540392] a living 
donor. 
13)Female subjects who are pregnant or lactating.  
 
STUDY ENDPOINTS  SAFETY:   
â€¢Overall incidence of adverse events and serious 
adverse events and relationship of AE and SAEs to the study treatment 
â€¢Need for HD in the [ADDRESS_1019071]-transplant. 
â€¢eGFR at 1M, 3M, 6M Patient and graft survival at Day 
180 
â€¢Rate of acute cellular rejection (ACR) and antibody 
mediated rejection at 6M 
 EFFICACY ASSESSMENTS:   
Primary Endpoints  Need for Dialysis in the [ADDRESS_1019072]-Transplant: 
(Excluding patients who get dialysis for hyperkalemia)  
â€¢The proportion of patients enrolled who require 
at least one session of dialysis in the first 
[ADDRESS_1019073] transplant.  
â€¢Number of dialysis sessions per patient in the 
first [ADDRESS_1019074] transplant.  
Renal Function and Graft Survival 6M 
â€¢eGFR at 6M post-transplant  
â€¢Patient & Graft survival 6M post-transplant 
 
Secondary Endpoints 
â€¢Rate of acute cellular and antibody mediated 
rejection epi[INVESTIGATOR_540404] 180  
â€¢Calculated creatinine clearance at 1M, days 90, 
180days post transplant. 
â€¢Development of DSAs at 6M 
â€¢SOC biopsies will be assessed at time of 
implantation and 6M post implantation.  
IMUNOSUPPRESSION  REGIMEN  â€¢Induction therapy using Thymoglobulin in divided 
doses (total of 6mg/kg) or Campath 1H 30mg SQ x 1. 
â€¢Calcineurin inhibition (Tacrolimus or Cyclosporine) 
will be initiated as per standard practice   
CONFIDENTIAL     C1INH (BerinertÂ®) IRI Study in Kidney Transplant  
	


â€¢MMF will be started per standard of care (SOC). 
â€¢Corticosteroids will be used per SOC. 
â€¢Valgancyclovir will be used as the prophylaxis for 
CMV for a minimum of 6 months.  
â€¢Prophylaxis for bacterial and fungal infection will 
be per institutional SOC.  
â€¢Diagnosis and treatment of acute cellular or 
antibody-mediated rejection will be per institutional SOC. 
STATISTICAL ANALYSIS Descriptive and comparative statistics will be used to 
evaluate results 
Study Timelines Phase 1:  Patient Entry . Once the study is approved by 
[CONTACT_745058], we anticipate a study entry period of up to 18-20 months to complete study entry. Phase 2: Follow Up to Study Completion . The next phase of 
the study will be having each subject complete the study which is [ADDRESS_1019075] an additional 6 months from completion of patient entry. 
Phase 3: Data collection, analysis and preparation of 
manuscript . Once every patient has completed the study, 
we anticipate an additional 6M to complete data collection, analysis and preparation of abstract presentations and manuscript.  Total Study Time : 36-40M (estimated) 
 
3. Investigator(s) And Other Study Participants  Information regarding additional key personnel involved in the conduct of 
the study, including names and contact [CONTACT_264899], monitors, clinical laboratories, technical departments, as well as information on members of additional study committees, will be found in the study files of the sponsor and on site if requested. 
A Data Safety Monitoring Board (DSMB) committee will review safety data. 
Quarterly assessment of AEs & SAEs will be performed and reported to FDA and 
Cedars-Sinai IRB. In addition, DSMB must be informed and may be convened at any time questions about safety arise and/or thromboembolic events occur. Please see appendix E FDA Guidance for Clinical Trial Sponsors.   
  4. Investigational Plan  4.1Study Design And Plan 
This is a Phase I/II double-blind, randomized, placebo-controlled study 
assessing safety and limited efficacy of intraoperative C1INH (500U/kidney) vs. Placebo administered into the graft renal artery 1-2 hours prior to implantation in adult subjects receiving a deceased donor kidney allograft considered high-risk for development of DGF (KDPI>80). Once eligible 
patients are identified, consented, and have an acceptable kidney transplant 
offer, they will be randomized by [CONTACT_451284]-Sinai Research Pharmacy to 
CONFIDENTIAL     C1INH (BerinertÂ®) IRI Study in Kidney Transplant  
	


receive study drug vs. placebo. Drug and placebo will be prepared by [CONTACT_745059]-Sinai Research Pharmacy and conveyed to the operating room in a blinded manner. The drug will be administered by [CONTACT_745060] a blinded manner.  
 4.1.1Study Drug Administration Timing 
In consideration of the latest time point of treatment application before 
graft reperfusion (ie. beginning of renal vein anastomosis), study 
treatments will be administered pre-operatively, 1-2 hours before graft 
reperfusion. Due to the biologic half-life of C1INH (approximately 2.5 to 
3.8 days), the time difference between early and late intraoperative 
treatment application, is thought to be negligible; however, we will administer the C1INH or placebo product at 1-2 hours prior to implantation for dosing consistency.  This will constitute the entirety of C1INH vs. placebo administration. The study format is shown below in figure 9.  
 
 
Figure 9:  Study format to evaluate C1INH in DGF. 
 
4.2Selection Of Study Population 
Persons legally incompetent to provide informed consent include, but may not be limited to, minors (children), individuals who are mentally incapable of understanding the implications of the PI/IC, and those who are physically unable, by [CONTACT_540423], physical or verbal means, to confirm their understanding and consent to take part in the study.  Our policy is not to 

CONFIDENTIAL     C1INH (BerinertÂ®) IRI Study in Kidney Transplant  
	


enter adult patients who are mentally incompetent to give informed consent.  
Exceptions must be approved by [CONTACT_600216]. 
 
Up to 40 adult men and women (18-77 years of age) who are recipi[INVESTIGATOR_22880] a kidney transplant and only a kidney allograft from a deceased donor who is high risk for DGF will be enrolled in the study (KDPI >80).  
 
4.2.1Inclusion Criteria 
Recipi[INVESTIGATOR_45982] 
1). Adult men or women (18-77 years of age) who are on chronic dialysis therapy and acceptable candidates for kidney transplant. 2). Understand and sign a written informed consent prior to study specific procedures. 3). Recipi[INVESTIGATOR_540395]. (A2 to B offers allowable) 4). AND one of the below criteria:  
a)Recipi[INVESTIGATOR_745022] >80  donors 
b) Recipi[INVESTIGATOR_745023] 
c) Recipi[INVESTIGATOR_745024] > 24 hours 
d)Recipi[INVESTIGATOR_745025]/CRRT prior to 
death/procurement  
e)Recipi[INVESTIGATOR_745028] â‰¥3.0 
mg/dL  
f)Patient risk a total risk index score of â‰¥3 based on the following: 
	

"		
 


 
	! 
"!
!
#




	
 ! 
 !#



	
 
	







	


 
	

	

	
 

#


	##

"


4.2.2 Exclusion Criteria  
1)Patients with a known pro-thrombotic disorder. (eg. Factor V Leiden) 
CONFIDENTIAL     C1INH (BerinertÂ®) IRI Study in Kidney Transplant  
	


2)Patients with a history of thrombosis or hyper-coagulable state, 
excluding access clotting. 
3)Patients with a history of administration of C1INH containing products or 
recombinant C1INH within 15 days prior to study entry. 
4)Patients with a known hypersensitivity to treatment with C1INH or blood 
products. 
5)Patients with an abnormal coagulation function. (INR >2, PTT> 50, 
PLT<60,000) who are not on anti-coagulation. 
6)Patients with known active presence of malignancies. 
7)Patients who are positive for Hep B, Hep C, or HIV PCR test. 
8)Recipi[INVESTIGATOR_540388]-emptive kidney transplantation. (unless baseline SCr is 
â‰¥4 mg/dL, making minimal urine output) 
9)All zero mismatch kidneys. 
10)Recipi[INVESTIGATOR_540389]-organ transplants. (kidney and any other organ) 
11)Recipi[INVESTIGATOR_745029]  
12)Recipi[INVESTIGATOR_540392] a living donor.  
13)Female subjects who are pregnant or lactating.   
  
4.3Removal Of Subjects From Study 
A subject who is withdrawn is one who discontinued in the clinical study for 
any reason. Subjects may be withdrawn from the study for the following reasons: 
â€¢At their own request or at the request of their legally acceptable 
representative. 
â€¢If, in the investigator's opi[INVESTIGATOR_1649], continuation in the study would be 
detrimental to the subject's well-being. 
â€¢At the specific request of the sponsor. 
In all cases, the reason for withdrawal must be recorded in the case report 
form and in the subject's medical records.   
Patients have the right to withdraw from the study at any time for any 
reason without penalty or prejudice.  The Investigator also has the right to withdraw patients from the study if he/she feels it is in the best interest of the patient or if the patient is uncooperative or non-compliant.  It is understood by [CONTACT_540425]-interpretable; therefore, unnecessary withdrawal of patients 
should be avoided.  Should a patient decide to withdraw, all efforts will be made to complete and report the observations, and early withdrawal procedures, as thoroughly as possible. 
The Investigator should contact [CONTACT_745061] a 
personal visit to determine as completely as possible the reason for the withdrawal.  A complete final evaluation at the time of the patientâ€™s withdrawal should be made with an explanation of why the patient is withdrawing from the study.  If the reason for removal of a patient from the study is an adverse event or an abnormal laboratory test result, the principal specific event or test will be recorded on the CRF.  For all patients who are withdrawn pre-maturely, every attempt should be made to 
assess the patientâ€™s status (i.e. patient and graft survival, malignancies, 
etc.) at [ADDRESS_1019076] dose of study medication. 
CONFIDENTIAL     C1INH (BerinertÂ®) IRI Study in Kidney Transplant  
	


4.4Premature Termination Of Study/Closure Of Center 
The sponsor has the right to close this study at any time, although this 
should occur only after consultation between involved parties. The Ethics Committee/Institutional Review Board (EC/IRB) must be informed. Should the study/center be closed prematurely, all study materials (except documentation that has to remain stored at site) will be retained on site by [CONTACT_456]/investigator.  
4.5Treatments 
4.5.1Treatments To Be Administered 
This study is designed with two blinded treatment groups (C1INH vs. 
Placebo). Each group will include 20 patients in a treatment arm and 20 patients in a placebo arm.  
This design is not statistically powered to show significant differences if 
there is a 30-50% reduction in the treatment group but may trend towards positive treatment effect since extensive DGF (40-50%)is expected in KDPI >80 recipi[INVESTIGATOR_840]. The dose of C1INH chosen is (500U/kidney) which should be sufficient to bind all endothelial surfaces in the transplanted kidney. This is based on our observations from our experience using C1INH vs. placebo to prevent antibody-mediated rejection in humans.  In those randomized to placebo, an equivalent volume of placebo (0.9% normal saline) will be administered prior to graft reperfusion. Both groups (C1INH or placebo) will 
receive an intrarenal administration of heparinized normal saline before 
study drug administration. 
Patients who fulfill all I/E criteria will be eligible to be enrolled into 
this Phase I/II study.  
4.5.2Identity Of Investigational Product(s) 
Medication will be labeled according to the requirements of local law and 
legislation.  Label text will be approved according to agreed CSMC Research Pharmacy procedures. 
Product name : [CONTACT_540440]
Â® / C1INH (Human) 
Chemical name : [CONTACT_540441] 1 Inhibitor (C1INH) 
Study Medication & Dosing : BerinertÂ® is available in a single-use vial that 
contains [ADDRESS_1019077] be reconstituted with 10 mL of diluent (sterile water) 
provided.  Prior to reconstitution, BerinertÂ® should be stored at 2Â° to 
25Â°C.  After reconstitution, administration may begin within 8 hours provided the solution has been stored at up to 25Â°C.  BerinertÂ® is dosed as a 500U/kidney infusion 1-2 hours prior to implantation of the KDPI >80 kidney. Participating patients will receive 500U/kidney C1 INH vs placebo (0.9% NS) prior to implantation, (see Appendix A). The C1INH or placebo dose will be preceded by [CONTACT_745062]. 
 
CONFIDENTIAL     C1INH (BerinertÂ®) IRI Study in Kidney Transplant  
	


	4.5.3Method Of Assigning Subjects To Treatment Groups 
Patients will be randomized into treatment/placebo arms in a 1:[ADDRESS_1019078] will maintain the randomization assignment. The Investigators, other study personnel, patients, and the Sponsor will be blinded to treatment assignment.   
4.5.4 Selection Of Doses In The Study 
[IP_ADDRESS] BerinertÂ® (C1INH Dosing) 
For the planned study, subjects will receive C1NH 500U/kidney infused into 
the renal artery pre-operatively 1-2 hours before graft reperfusion. For all dose reconstitutions, BerinertÂ® is provided in single dose vials of 500 units. Each vial will be reconstituted in 10 ml sterile water for injection.  Placebo will be administered in an identical volume. C1INH will be preceded by [CONTACT_745063]. 
 [IP_ADDRESS] Placebo Dosing The placebo used in this study will be 0.9% normal saline administered as a 
single dose into the renal artery, 1-2 hours before graft reperfusion. The 
total volume will be identical to that calculated for BerinertÂ® infusions. 
Placebo will be preceded by [CONTACT_745063]. 
 4.5.[ADDRESS_1019079] that the patients enrolled into this study are at high risk for developi[INVESTIGATOR_745030].   
[IP_ADDRESS] Induction Antibody Therapy All patients enrolled into this study will be treated with induction 
antibody therapy with ThymoglobulinÂ® OR Campath 1H. For ThymoglobulinÂ®, the 
first dose will be given immediately after the transplantation procedure to follow with additional doses so that patients receive up to 6 mg/kg (1.5mg/kg/dose) using standard institutional treatment guidelines for use of this agent in this patient population. Campath 1H will be administered in a single [ADDRESS_1019080]-transplant. No induction administration of IL-2 receptor inhibitors is permitted in this protocol.  
 
CONFIDENTIAL     C1INH (BerinertÂ®) IRI Study in Kidney Transplant  
	



[IP_ADDRESS] Maintenance Immunosuppression 
[IP_ADDRESS].1 Calcineurin Inhibitors (Tacrolimus or Cyclosporine) 
Tacrolimus (Prograf) and Cyclosporine (Neoral) are indicated for the 
prophylaxis of organ rejection in patients receiving allogeneic kidney transplants. Tacrolimus or Cyclosporine will be initiated and monitored with trough levels using standard institutional treatment guidelines for use of these agents in this patient population. If conversion to belatacept is deemed necessary per SOC process, this is allowable during study 
participation 
[IP_ADDRESS].2 Mycophenolate Mofetil(MMF) 
Mycophenolate mofetil (MMF, CellCept), the morpholinoethylester of 
mycophenolic acid, has been shown to have antiproliferative effects on lymphocytes by [CONTACT_540428] T- and B-lymphocytes. MMF will be dosed using standard institutional treatment guidelines for use of these agents in this patient population. Myfortic can be used instead of CellCept and will be dosed using standard institutional treatment guidelines for use of these agents in this patient population. 
[IP_ADDRESS].[ADDRESS_1019081] 
The active treatment arm (BerinertÂ® 500U/kidney) will be compared to a 
placebo control treatment arm, with a total of [ADDRESS_1019082] dropouts. This design is 
not statistically powered to show differences in DGF; a 30-50% reduction in DGF predicted for the BerinertÂ® study group. Treatment effect will be investigated following renal artery infusion with BerinertÂ® or an equivalent volume of placebo (0.9% normal saline) pre-operatively prior to graft reperfusion.  The C1INH or placebo dose will be preceded by [CONTACT_745062]. 
If a patient is enrolled into the study but the transplant does not occur as 
planned (e.g. transplant is cancelled due to donor organ quality at time of transplant), the patient will be considered a â€œscreening without transplantâ€. The patient will be maintained on the study ID # that was 
assigned 

		
CONFIDENTIAL     C1INH (BerinertÂ®) IRI Study in Kidney Transplant  
	


at enrollment but will not be followed past the screening day. IF the 
patient receives another transplant offer (at any time while study enrollment is still open), the patient will be allowed to continue with the study protocol, with Day of Transplant = Day 0, as if the screening and consenting occurred during the current admission.  
 4.5.[ADDRESS_1019083] will be contact[CONTACT_745064] a patientâ€™s eligibility.  The pharmacist will prepare the 
blinded study medication or placebo. The study treatment will be prepared according to a pharmacist-supplied randomization code (blinded from all other study personnel). The study treatment will be prepared in a non-siliconized sterile syringe (BerinertÂ® {500U} for all individuals) and labeled with: 
â€¢Protocol Number 
â€¢Screening number  
â€¢Randomization number. 
The pharmacist will check the non-siliconized IV syringe for potential 
particulates. If none are found, the blinded syringe of study treatment, 
labeled as stated above, will be transported to the surgical suite and matched with the matching patient chart. For the placebo arm, an equivalent volume of normal saline will be prepared in an identical dispensing medium as the C1INH product, labeled as stated above, and transported to the surgical suite and matched with the matching patient chart. Before the study treatment (Berinert or placebo), heparinized normal saline will be administered to the allograft. This method of drug administration has not been FDA approved and may have unforeseen risks  
In case of a medical emergency, the study drug assignment for a particular 
patient may be unblinded. Unblinding study drug assignment will only be necessary if knowledge about treatment is needed for the medical management of the patient. The patientâ€™s treatment assignment can be identified for 
unblinding purposes by [CONTACT_540430] (310-423-
6580). When this is necessary, the investigator must immediately notify the IRB, and document the reason and date of the un-blinding. The event must also be documented on the study termination record, the AE page of the CRF, and in source documents. Additionally, the Principal Investigator [INVESTIGATOR_745031] a written explanation describing the event within [ADDRESS_1019084] approximately 
60-120 minutes prior to graft reperfusion administered pre-operatively.  
CONFIDENTIAL     C1INH (BerinertÂ®) IRI Study in Kidney Transplant  
	


4.6Study Variables 
4.6.1Efficacy Variables 
[IP_ADDRESS] Primary Efficacy Endpoints  
For patients who require dialysis in the first 30 days: ( Excluding 
patients who get dialysis for hyperkalemia)  
â€¢The proportion of patients enrolled who require at least one 
session of dialysis in the first [ADDRESS_1019085] transplant.  
â€¢Number of dialysis sessions per patient in the first [ADDRESS_1019086]-transplant.  
Renal function and graft survival 6M 
â€¢eGFR at 6M post-transplant 
â€¢Patient and graft survival at 6M post-transplant 
 
[IP_ADDRESS] Secondary Efficacy Endpoints 
â€¢Calculated Creatinine Clearance obtained at 1M, 3M, 6M post-transplant.  
â€¢Rate of acute cellular and antibody mediated rejection epi[INVESTIGATOR_540404] 
180  
â€¢Development of DSAs at 6M 
â€¢Analysis of renal transplant biopsies at time of implantation and at 6M 
as clinically indicated. 
 
4.6.2Safety Variables 
[IP_ADDRESS] Adverse Drug Reactions : The most serious adverse reaction reported 
in subjects in clinical studies who received BerinertÂ® was an increase in the severity of pain associated with hereditary angioedema.  In a placebo controlled clinical study, the incidence of adverse events occurring in more 
than 4% of subjects (n = 43) receiving BerinertÂ® up to 72 hours after 
infusion was nausea (7%), headache (7%), abdominal pain (7%), dysgeusia (4.7%), vomiting (2.3%), pain (2.3%), and muscle spasms (2.3%).   Adverse reactions can persist 7-[ADDRESS_1019087] been reported to be abdominal pain (6.5%), diarrhea (4.6%), nausea (6.5%), vomiting (4.6%), headache (11.1%), hereditary angioedema recurrence (11.1%), muscle spasm (5.6%), and pain (5.6%).  Subjects were tested at baseline and after [ADDRESS_1019088]-marketing reports from Europe since 1979 in patients receiving BerinertÂ® for treatment of HAE include hypersensitivity/anaphylactic reactions, a few 
suspected cases of viral transmission, including cases of acute hepatitis C, 
injection-site pain, injection-site redness, chills, and fever. See Novation Drug Monograph for BerinertÂ®. BerinertÂ® was well tolerated with minimal AE/SAE profile in our kidney transplant studies (Appendix B).   [IP_ADDRESS] Assessment of Risk for Thrombotic Events with C1INH Administration:  
Patients with known risk factors for thrombotic events will be monitored for signs and symptoms of thrombosis, such as new onset swelling and pain in the 
CONFIDENTIAL     C1INH (BerinertÂ®) IRI Study in Kidney Transplant  
	


limbs or abdomen, new onset chest pain, shortness of breath, loss of 
sensation or motor power, or altered consciousness, vision, or speech. Patients will be assessed for evidence of DVT or other TEs per the usual 
standard process. Routine measurements of coagulation factors to evaluate 
DIC (D-Dimers, fibrinogen, PT, PTT) will be performed per standard process. 
  [IP_ADDRESS] Evidence of a Thrombotic Effect of C1INH Administration when Given 
in Supraphysiologic Dosages to Humans: The German Medical Professionâ€™s Drugs 
Committee (AkdÃ…) reported on 13 cases of severe thrombus formation after BerinertÂ® infusions. These infusions were given to neonates undergoing cardiac surgery and doses of BerinertÂ® were given at exceedingly high doses (~500U/kg) without control studies (see Appendix C). Nine of these infants died of this complication. The conclusions from this report are as follows:   
â€¢There are no studies to support the use of C1INH outside of those with 
hereditary angioneurotic edema.  
â€¢The use of C1INH in patients who do not have C1INH deficiency may result 
in abnormal coagulation parameters with propensity to thrombosis. 
â€¢There are no controlled studies that suggests a benefit of C1INH therapy 
in conditions other than C1INH deficiency.  
â€¢Any proposed uses outside of C1INH deficiency should be conducted in a 
controlled manner to monitor for unexpected or unanticipated side effects of C1INH therapy. 
 Clearly, this is a serious and unanticipated complication of C1INH therapy that could potentially limit its use in patients with other conditions where complement inhibition would be desirable. This is the case with our proposal.  Inhibition of complement activation post-transplant has great potential for prevention of complement-dependent DGF. In addition, there is an important unmet need for new therapeutics in the prevention and treatment 
of DGF. Despi[INVESTIGATOR_6831], it is important to assess the tolerability and safety 
of C1INH therapy in this patient population. Although the C1INH dosing proposed in our study is much less than that reported to be associated with TE and well below therapeutic dosing recommendations (20-50U/kg) (500U/kidney once on Day 0), and will be administered intra-renally, there is still a possibility that increasing C1INH levels above normal baseline could have deleterious effects and induce coagulation abnormalities. Recent safety data from clinical trials of C1INH for use in C1INH deficiency have not reported TE with one exception of a basilar artery thrombosis in a patient treated for C1INH deficiency (Appendix C). This event was deemed unrelated to C1INH therapy. As previously indicated if significant coagulation abnormalities or TE events are seen in any study patient, the 
study will be terminated. However, data from our recently completed study of 
C1INH in prevention of antibody-mediated rejection ([STUDY_ID_REMOVED]) in a 
randomized placebo controlled study showed no evidence of thrombotic events 
in any patient treated with BerinertÂ® at 20U/kg x [ADDRESS_1019089]-transplant. In addition, recent reports from the FDA 
(Gandhi et al) suggests that thrombotic events do occur with C1INH therapy, 
but most cases are associated with the product (CinryzeÂ®).  
 
 
CONFIDENTIAL     C1INH (BerinertÂ®) IRI Study in Kidney Transplant  
	


[IP_ADDRESS] Evidence of a Thrombotic Effect of C1INH Administration when Given 
in Supra-physiologic Dosages to Animals:  Data on C1INH transgenic mice show 
that blood levels as high as 2mg/ml (NL 25 Î¼g/ml) are produced without 
reported effects (34)(Appendix D). Other investigators have shown that ischemia-reperfusion injury is reduced in animals transgenic for C1INH expression (Appendix D).   Data provided by [CONTACT_489208] (Appendix D) shows that administration of BerinertÂ® up to 200U/kg daily for 14 days had no 
deleterious effects and did not induce coagulation abnormalities.   
 [IP_ADDRESS] Therapy Stoppi[INVESTIGATOR_745032], the study will be halted and re-evaluated by [CONTACT_745065], thromboembolic events (TE) or evidence of coagulation abnormalities that would suggest impending TE. In addition, the study will be halted or stopped if any other known or unexpected AEs attributable to C1-inhibitor occur.  Reassessment of the study goals and complications will be done and discussed with the DSMB prior to proceeding. A summary report will be submitted to the IRB and FDA. 
[IP_ADDRESS] Primary Safety Endpoints 
â€¢Overall incidence of adverse events and serious adverse events 
and relationship to the study treatment including but not limited to, occurrence of infections, thrombosis of the allograft, vascular thromboses, bleeding, death, vital signs, and abnormal lab values. 
[IP_ADDRESS] Secondary Safety Endpoints 
â€¢Chemistry and coagulation parameters 
â€¢eGFR at 1M, 3M, 6M 
â€¢Patient survival at day 180 
â€¢Graft survival at day 180 
â€¢Rate of acute cellular and antibody mediated rejection epi[INVESTIGATOR_745033] 180 
â€¢Rate of de novo Donor Specific Antibody (DSA) development 
4.6.3Assessment Periods 
[IP_ADDRESS] Screening Procedure â€“Day [ADDRESS_1019090] be documented in the patientâ€™s source documents and evidenced by [CONTACT_745066]. 
After signing the ICF, each patient will be assigned a patient identifier 
number that will be used on all subject documentation. Numbers will be assigned in ascending sequential order. This number will also correspond to the patient number entered on study materials. 
The Principal Investigator [INVESTIGATOR_745034]-investigator will 
review the inclusion and exclusion criteria and laboratory test data to confirm eligibility of each subject. 
The screening procedures will include the following:  
CONFIDENTIAL     C1INH (BerinertÂ®) IRI Study in Kidney Transplant  
	


â€¢Informed consent 
â€¢Medical history 
â€¢Inclusion/Exclusion criteria review 
â€¢Vital signs/weight 
â€¢Complete physical examination  
â€¢Hematology & chemistry profile 
â€¢Record PT, PTT, INR collected by [CONTACT_2946] 
â€¢Review historical serologies for HIV, HBV, HCV, CMV and EBV, collected 
by [CONTACT_2946]  
â€¢Concomitant medications 
â€¢Review of previous Pneumococcal vaccination  
â€¢Review of Pregnancy test (for WOCP, Age 12-55 years old) 
 
[IP_ADDRESS] Day 0 â€“ Day of Transplantation 
â€¢Vital signs (pre- and post-transplant) 
â€¢Physical examination (pre- and post-transplant) 
â€¢Randomization (pre-transplant) 
â€¢Hematology & chemistry profile (pre- and post-transplant) 
â€¢Record PT, PTT and INR collected by [CONTACT_2946] (pre-transplant) 
â€¢Concomitant medications (pre- and post-transplant) 
â€¢ECG (pre-transplant) 
â€¢Chest x-ray (pre-transplant) 
â€¢Serum Creatinine (pre-and post-transplant) 
â€¢Berinert vs. Placebo infusion (on call to OR) with heparinated saline 
â€¢Campath 1H or Thymoglobulin administration 
â€¢Assessment of implantation biopsy (if collected) 
â€¢Urine output measurement if producing urine (post-transplant) 
â€¢Adverse event assessment 
â€¢Dialysis assessment 
 
[IP_ADDRESS] Day 1-7 Assessments measured on days 1, 3 and 7 (or until discharge) 
â€¢Concomitant medications 
â€¢Serum creatinine measurements through Day 7 or until discharge.   
â€¢Dialysis assessment 
â€¢Physical examination 
â€¢Vital Signs/weight 
â€¢Calculated estimated GFR 
â€¢Record Urine output measurement if producing urine 
â€¢Adverse event assessment 
â€¢Hematology & chemistry profile 
â€¢Urinalysis if producing urine. Urinary IL-18 to be collected on two 
days, between day 1 to 7, if producing urine and testing is available 
 
CONFIDENTIAL     C1INH (BerinertÂ®) IRI Study in Kidney Transplant  
	


[IP_ADDRESS] Day 30 Â± 7 days 
â€¢Concomitant medications 
â€¢Physical examination (may occur as a video visit) 
â€¢Vital Signs/weight 
â€¢Dialysis assessment  
â€¢Adverse Event Assessment 
â€¢Calculated estimated GFR 
â€¢  Hematology & chemistry profile 
â€¢Urinalysis  
 
[IP_ADDRESS] Days 90, 180 Â±30 days 
â€¢Concomitant medications  
â€¢Physical examination(may occur as a video visit) 
â€¢Dialysis assessment  
â€¢Vital Signs/weight 
â€¢Adverse Event Assessment 
â€¢Calculated estimated GFR 
â€¢  Hematology & chemistry profile 
â€¢Urinalysis  
â€¢ACR assessment on Day 180  
â€¢Assessment of SOC biopsies on Day 180 
â€¢Patient survival assessment on day 180 
â€¢Graft survival assessment on day 180 
â€¢Donor Specific Antibody (DSA) assessment at Day 180 
 
4.6.4Observations And Measurementsâ€”see Appendix A. 
 
[IP_ADDRESS] Physical Examination 
A complete physical examination will include;  the examination of the following 
body systems: general appearance, skin, HEENT (head, ears, eyes, nose, 
throat), cardiovascular, pulmonary, abdomen, neurological, lymph nodes, spi[INVESTIGATOR_98243] (skeletal). Patient visits may occur as video visits with the 
MD as per standard of care procedures.  
 
[IP_ADDRESS] Vital Signs 
Vital signs; including blood pressure, heart and respi[INVESTIGATOR_745035]. Height will be measured at the screening visit only.  [IP_ADDRESS] Serum Creatinine 
Serum creatinine levels will be measured per institutional SOC.  [IP_ADDRESS] Calculated GFR 
Estimated GFR will be calculated using the MDRD formula.  
 
CONFIDENTIAL     C1INH (BerinertÂ®) IRI Study in Kidney Transplant  
	


[IP_ADDRESS] Urine Output 
Urine output will be collected and recorded for the first 0-[ADDRESS_1019091]-transplant, until patient discharge.  [IP_ADDRESS] PT, PTT and INR Tests 
PT, PTT and INR tests will be performed per institutional SOC.  [IP_ADDRESS] Hematology and Chemistry Profile 
Hematology and Chemistry profile performed per institutional SOC  
 [IP_ADDRESS] ECG Testing 
An ECG will be performed per institutional SOC.  [IP_ADDRESS] ACR Assessment 
An acute rejection assessment will be recorded on patients who were diagnosed with an ACR grade â‰¥ Grade 2 per the Banff grading system and 
received anti-rejection therapy.  [IP_ADDRESS] Rate and Duration of Dialysis 
Duration of dialysis will be measured by [CONTACT_745067] [ADDRESS_1019092] transplant.  As for rate of 
dialysis, one dialysis session will represent the need for dialysis 
treatment. 
4.7Data Quality 
Monitoring and auditing procedures defined/agreed by [CONTACT_745068], in order to comply with Good Clinical Practice (GCP) guidelines. Our center will be monitored at quarterly to ensure compliance with the study protocol, GCP and legal aspects. This will include on-site checking of the case report forms (CRF) for completeness and clarity, cross checking with source documents, and clarification of administrative matters. 
4.8Documentation 
Entries made in the CRF must be either verifiable against source documents, 
or have been directly entered into the CRF, in which case the entry in the CRF will be considered as the source data.  The source data parameter to be 
verified and the identification of the source document must be documented. 
The study file and all source data should be retained until notification given by [CONTACT_142086]. 
 5Ethical And Legal Aspects 
5.1Ethics Committee (EC) Or Institutional Review Board (IRB) 
Documented approval from appropriate IRBs will be obtained prior to study 
start, according to GCP, local laws, regulations and organizations. When necessary, an extension, amendment or renewal of the IRB approval must be obtained and retained in site files.  IRB must supply to the sponsor, upon request, a list of the IRB Committee members involved in the vote and a statement to confirm that the IRB Committee is organized and operates according to GCP and applicable laws and regulations. 
 
CONFIDENTIAL     C1INH (BerinertÂ®) IRI Study in Kidney Transplant  
	


5.2Ethical Conduct Of The Study 
The procedures set out in this protocol, pertaining to the conduct, 
evaluation, and documentation of this study, are designed to ensure that the sponsor and investigator abide by [CONTACT_745069] 1989 version of the Declaration of Helsinki .  The 
study will also be carried out in keepi[INVESTIGATOR_39684](s) and regulation(s).  This may include an inspection by [CONTACT_142081]/or Regulatory Authority representatives at any time.  
The investigator agrees to the inspection of study-related records by [CONTACT_745070]/sponsor representatives, and must allow direct access to source documents to the Regulatory Authority/sponsor representatives.   
Modifications to the study protocol will not be implemented by [CONTACT_745071]. However, the investigator may implement a deviation form, or a change of, the protocol to eliminate an immediate hazard(s) to the trial subjects without prior IRB/Sponsor approval/favorable opi[INVESTIGATOR_1649]. As soon as possible, the implemented deviation or change, the reasons for it and if appropriate the proposed protocol amendment should be submitted to the IRB/Sponsor. Any deviations from the protocol must be fully explained and documented by [CONTACT_093]. 
 5.3Regulatory Authority Approvals/Authorizations 
Regulatory Authority approvals/authorizations/ notifications, where 
required, must be in place and fully documented prior to study start. 
 5.4Subject Information And Consent 
The Informed Consent Form (ICF) will be provided. Prior to the beginning of 
the study, the investigator must have the IRB written approval/favorable opi[INVESTIGATOR_745036].  The written approval of the IRB together with the approved subject information/ICF must be filed in the study files. 
Written informed consent must be obtained before any study specific 
procedure takes place.  Participation in the study and date of informed 
consent given by [CONTACT_745072]â€™s files. 
Discussion of the study with the patient will occur in person or via phone. 
While patients may be approached soon after their visit and/or admission begins, they can take time to consider and discuss participation with others before deciding. All questions will be answered by [CONTACT_108972]. In rush/emergency transplant cases, the study will not be offered. If the patient wishes to enroll in the study, consenting will occur in person with a paper ICF or via phone conversation using DocuSign. The process followed will be fully documented with a consent 
progress note.  
 
CONFIDENTIAL     C1INH (BerinertÂ®) IRI Study in Kidney Transplant  
	


	5.5Confidentiality 
All records identifying the subject will be kept confidential and, to the 
extent permitted by [CONTACT_29695]/or regulations, will not be made publicly available. 
Subject names will not be supplied to the sponsor. Only the subject number 
and subject initials will be recorded in the case report form, and if the subject name [CONTACT_75502] (e.g., pathologist report), it must be obliterated before a copy of the document is supplied to the 
sponsor.  Study findings stored on a computer will be stored in accordance 
with local data protection laws.  The subjects will be informed in writing that representatives of the sponsor, EC/IRB, or Regulatory Authorities may inspect their medical records to verify the information collected, and that all personal information made available for inspection will be handled in strictest confidence and in accordance with local data protection laws. 
If the results of the study are published, the subjectâ€™s identity will 
remain confidential.  
The investigator will maintain a list to enable subjectsâ€™ records to be 
identified. 
 6Statistical Methods And Determination Of Sample Size 
6.1Statistical And Analytical Plans 
Determination of Sample Size 
Since this pi[INVESTIGATOR_745037] a novel 
method of administration of C1INH, sample size determination was not performed. 

7Adverse Events (AEs) 
7.1Adverse Event (AE) Monitoring 
7.2Adverse Event (AE) Definitions 
7.2.1Adverse Events (AEs) 
An AE is any untoward medical occurrence in a subject or clinical 
investigation subject administered with a pharmaceutical product. The AE does not necessarily have to have a causal relationship with this treatment.  An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of an investigational product, whether or not considered related to the medicinal product. 
Adverse events associated with the use of a drug in humans, whether or not 
considered drug related, include the following:  
â€¢An AE occurring in the course of the use of a drug product in professional 
practice, 
â€¢An AE occurring from an overdose whether accidental or intentional, 
â€¢An AE occurring from drug abuse,  
â€¢An AE occurring from drug withdrawal.  
CONFIDENTIAL     C1INH (BerinertÂ®) IRI Study in Kidney Transplant  
	



â€¢An AE where there is a reasonable possibility that the event occurred 
purely as a result of the subjects participation in the study (e.g. adverse event or serious adverse event due to discontinuation of anti-hypertensive drugs during wash-out phase) must also be reported as an adverse event even if it is not related to the investigational product. 
The clinical manifestation of any failure of expected pharmacological action 
is not recorded as an AE if it is already reflected as a data point captured in the CRF.  If, however, the event fulfills any of the criteria for a â€œseriousâ€ AE (SAE), it must be recorded and reported as such. 
 
7.2.2Serious Adverse Event (SAE) 
An SAE is any untoward medical occurrence that at any dose:  
â€¢results in death 
â€¢is life-threatening 
â€¢requires in-patient hospi[INVESTIGATOR_6929] 
â€¢results in persistent or significant disability or incapacity 
â€¢is a congenital anomaly or birth defect 
â€¢is an important medical event 
Life-threatening:  The term â€œlife-threateningâ€ in the definition of â€œseriousâ€ 
refers to an adverse event in which the subject was at risk of death at the 
time of the event. It does not refer to an adverse event which 
hypothetically might have caused death if it were more severe. 
Hospi[INVESTIGATOR_059]:  Any AE leading to hospi[INVESTIGATOR_330733], UNLESS at least one of the following exceptions are met: 
â€¢The admission is pre-planned (i.e., elective or scheduled surgery 
arranged prior to the start of the study)    
OR 
â€¢The admission is not associated with an adverse event (e.g., 
social hospi[INVESTIGATOR_8933])   
However, it should be noted that invasive treatment during any 
hospi[INVESTIGATOR_39675] â€˜medically importantâ€™ and as such may be reportable as an SAE dependent on clinical judgment.  In 
addition, where local regulatory authorities specifically require a more 
stringent definition, the local regulation takes precedent. 
Disability :  a substantial disruption of a personâ€™s ability to conduct 
normal lifeâ€™s functions. 
Important medical event : Any adverse event may be considered serious because 
it may jeopardize the subject and may require intervention to prevent another serious condition. As guidance for determination of important medical events refer to the â€œ WHO Adverse Reaction Terminology â€“ Critical 
Terms Listâ€ . These terms either refer to or might be indicative of a serious 
disease state.  
CONFIDENTIAL     C1INH (BerinertÂ®) IRI Study in Kidney Transplant  
	


Such reported events warrant special attention because of their possible 
association with a serious disease state and may lead to more decisive action than reports on other terms. 
SAE medwatch reports  WILL NOT be filled out for any prolonged hospi[INVESTIGATOR_745038]â€™ primary disease (ESRD).  For example, prolonged admissions for dialysis or readmission for fluid overload as a consequence of ESRD since this this is an expected complication of the patientsâ€™ disease state and not 
related to study drug. These events will be adjudicated by [CONTACT_978]. 
Otherwise, all SAEs medwatch reports will be submitted to the IRB, and FDA.  
 7.2.3Unexpected Adverse Event (AE) 
An unexpected AE is any adverse drug event, the specificity or severity of 
which is not consistent with the current Investigator Brochure (or Package Insert for marketed products). Also, reports which add significant information on specificity or severity of a known, already documented adverse event constitute unexpected AEs. For example, an event more specific or more severe than described in the Investigator Brochure would be considered â€œunexpectedâ€. Specific examples would be; (a) acute renal failure as a labeled adverse event with a subsequent new report of interstitial nephritis and (b) hepatitis with a first report of fulminant hepatitis. 
 
7.2.4Relationship Of Adverse Event To Investigational Product 
The assessment of the relationship of an AE to the administration of study 
drug is a clinical decision based on all available information at the time of the completion of the case report form. 
An assessment of â€˜Noâ€™ would include: 1. The existence of a clear alternative explanation, e.g., mechanical 
bleeding at surgical site; or 
2. Non-plausibility, e.g., the subject is struck by [CONTACT_745073]; cancer developi[INVESTIGATOR_007] a few days after the first drug administration.  
An assessment of â€˜Yesâ€™ indicates that there is a reasonable suspi[INVESTIGATOR_745039]. 
Factors to be considered in assessing the relationship of the adverse event 
to study drug include:  
â€¢The temporal sequence from drug administration: The event should occur 
after the drug is given.  The length of time from drug exposure to event should be evaluated in the clinical context of the event 
â€¢Recovery on discontinuation (de-challenge), recurrence on reintroduction 
(re-challenge): Subjectâ€™s response after drug discontinuation (de-challenge) or subjectâ€™s response after drug re-introduction (re-challenge) should be considered in the view of the usual clinical course of the event in question 
CONFIDENTIAL     C1INH (BerinertÂ®) IRI Study in Kidney Transplant  
	


â€¢Underlying, concomitant, intercurrent diseases: Each report should be 
evaluated in the context of the natural history and course of the disease being treated and any other disease the subject may have 
â€¢Concomitant medication or treatment: The other drugs the subject is 
taking or the treatment the subject receives should be examined to determine whether any of them may be suspected to cause the event in 
question 
â€¢The pharmacology and pharmacokinetics of the test drug: The 
pharmacokinetic properties (absorption, distribution, metabolism and excretion) of the test drug(s), coupled with the individual subjectâ€™s pharmacodynamics should be considered. 
 
7.2.5Severity Of The Adverse Event (AE) 
The following classification should be used: The severity of AEs should be graded as follows: 
â€¢Mild â€“ usually transient in nature and generally not interfering with 
normal activities 
â€¢Moderate â€“ sufficiently discomforting to interfere with normal activities 
â€¢Severe â€“ prevents normal activities. 
 7.2.6Adverse Event (AE) Documentation 
All AEs occurring after the subject has signed the informed consent must be 
fully recorded in the subjectâ€™s case record form. 
Documentation must be supported by [CONTACT_36927]â€™s file.  A 
laboratory test abnormality considered clinically relevant, e.g., causing the subject to withdraw from the study, requiring treatment or causing apparent clinical manifestations, or judged relevant by [CONTACT_093], should be reported as an AE.  Each event should be described in detail along 
with start and stop dates, severity, relationship to investigational 
product, action taken and outcome. 
 7.3Reporting of Serious Adverse Events (SAEs) or Pregnancy 
Serious adverse events (SAEs), including laboratory test abnormalities 
fulfilling the definition of serious, after signing the informed consent and during follow-up period must immediately (within 24 hours of the investigatorâ€™s awareness) be reported to the person detailed in the study file.  A Serious Adverse Event Form  must also be completed within [ADDRESS_1019093] be reported to the IRB and FDA in accordance 
CONFIDENTIAL     C1INH (BerinertÂ®) IRI Study in Kidney Transplant  
	


with the signed Pharmacovigilance Agreement, which will also be included in 
the study file and regulatory binder.  
Pregnancy occurring during a clinical investigation, although not considered 
an SAE, must be reported to the IRB within the same timelines as an SAE on a Pregnancy Monitoring Form . The outcome of a pregnancy should be followed up 
carefully and any abnormal outcome of the mother or the child should be reported. This also applies to pregnancies following the administration of the investigational product to the father prior to sexual intercourse. 
CONFIDENTIAL     C1INH (BerinertÂ®) IRI Study in Kidney Transplant  
	


8References 
1. [LOCATION_002] Renal Data System: 2015 USRDS Annual Data 
Report: Epi[INVESTIGATOR_47640], Bethesda,MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2015 
 
2. Butala NM, Reese PP, Doshi MD, Parikh CR: Is delayed graft function causally associated with long-term outcomes after kidney transplantation? Instrumental variable analysis. Transplantation 95: 1008â€“1014, 2013  
3. WuWK, FamureO, LiY, KimSJ: Delayed graft function and the risk 
of acute rejection in the modern era of kidney transplantation. Kidney Int 88: 851â€“858, 2015  4. Lim WH, Johnson DW, Teixeira-Pi[INVESTIGATOR_1946] A, Wong G: Association 
between duration of delayed graft function, acute rejection, and 
allograft outcome after deceased donor kidney transplantation. Transplantation 103: 412â€“419, 2019  5. Singh SK, KimSJ: Epi[INVESTIGATOR_745040].Clin JAm Soc Nephrol 
11: 317â€“323, 2016  6. Gill J, Rose C, Lesage J, Joffres Y, Gill J, Oâ€™Connor K: Use andoutcomes of kidneys from donation after circulatory death donorsin the [LOCATION_002]. J Am Soc 
Nephrol 28: 3647â€“3657, 
2017  7.Kumar S: Cellular and molecular pathways of renal repair after acute kidney injury. Kidney Int 93: 27â€“40, 2018  
 
8. McCullough JW, Renner B, Thurman JM: The role of the complement system in acute kidney injury. Semin Nephrol 33: 543â€“ 556, [ADDRESS_1019094], Jordan SC: Potential roles for C1 inhibitor in 
transplantation. Transplantation 100: 1415â€“1424, [ADDRESS_1019095], Heeger PS. Complement Dependence of Murine Costimulatory Blockade-Resistant Cellular Cardiac 
Allograft Rejection. Am J Transplant. 2017 Nov;17(11):2810-2819. 
 11. WeiserMR, Williams JP, MooreFDJr., Kobzik L,M aM, Hechtman HB, Carroll MC: Reperfusion injury of ischemic skeletal muscle is mediated by [CONTACT_745074]. J Exp Med 183: 
2343â€“2348, [ADDRESS_1019096] CE, Stover CM: Targeting of mannan-binding lectin-
associated serine protease-2 confers protection from myocardial and 
gastrointestinal ischemia/ reperfusion injury. Proc Natl Acad Sci [LOCATION_003]108: 7523â€“7528, 2011  13.CippÃ , P.E., Liu, J., Sun, B. et al. A late B lymphocyte action in dysfunctional 
tissue repair following kidney injury and transplantation. Nat Commun 10, 1157 
(2019) doi:10.1038/s41467-019-[ZIP_CODE]-2 
CONFIDENTIAL     C1INH (BerinertÂ®) IRI Study in Kidney Transplant  
	


 
14. Daly PJA, Power RE, Healy DA, Hickey DP, Fitzpatrick JM and Watson RWG (2005) 
Delayed graft function: a dilemma in renal transplantation. BJU International 
96:498-501.   15. Cockcroft DW and Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16(1):31-41. 
 
16. Humar A, Payne WD, Sutherland DE, Matas AJ (2000) Clinical determinants of multiple acute rejection epi[INVESTIGATOR_663404]. Transplantation 69:2357-60.  
17. Hetzel GR, Grunberg W, Boltres A, Plum A, et al (2002) Influence of delayed 
graft function on glomerular hemodynamics and permselectivity in well-functioning renal allografts. Transplant Proc 34:2203-4.  18. Boom H, Mallat MJK, De Fijter JW, Zwinderman AH and Paul LC (2000) Delayed 
graft function influences renal function, but not survival. Kidney International 
58:859-866.  19. Gonwa TA, Mai ML, Smith LB, et al (2002) Immunosuppression for delayed or slow graft function in primary cadaveric renal transplantation. Use of low dose 
tacrolimus therapy with post-operative administration of anti-CD25 monoclonal 
antibody. Clin Transplant 16:144-9.  20. Halloran PF, Hunsicker LG (2001) Delayed graft function. State of the art. Summit meeting, Scottsdale, Arizona, [LOCATION_003], November 10-11, 2000. Am J Transplant 
1:115-20. 
 21. Summers DM, Johnson RJ, Allen J, et al. Analysis of factors that affect outcome after transplantation of kidneys donated after cardiac death in the [LOCATION_006]: A cohort study. Lancet 2010; 376: 1303â€“1311. 
 
22.Nauser CL, Farrar CA, Sacks SH. Complement Recognition Pathways in Renal 
Transplantation. J Am Soc Nephrol. 2017 Sep;28(9):2571-2578.  
 
23.Naesens M, Li L, Ying L, Sansanwal P, Sigdel TK, Hsieh SC, Kambham N, Lerut E, 
Salvatierra O, Butte AJ, Sarwal MM. Expression of complement components differs 
between kidney allografts from living and deceased donors.  
J Am Soc Nephrol. 2009 Aug;20(8):1839-51. 
 24. Schroppel B et al. Peritransplant eculizumab does not prevent delayed graft 
function in deceased donor kidney transplant recipi[INVESTIGATOR_840]: Results of two randomized 
controlled pi[INVESTIGATOR_4250].  Am J Transplant.  2019 Aug 26. doi: 10.1111/ajt.[ZIP_CODE]. 
[Epub ahead of print] 
 25. Jordan SC, Choi J, Aubert O, Haas M, Loupy A, Huang E, Peng A,Kim I, Louie S, 
Ammerman N, Najjar R, Puliyanda D, Vo A: A phase I/II, double-blind, placebo-
controlled study assessing safety and efficacy of C1 esterase inhibitor for prevention of delayed graft function in deceased donor kidney transplant recipi[INVESTIGATOR_840] . Am J Transplant 18: 2955â€“2964, [ADDRESS_1019097] MC, Fanelli G, Farrar CA and Sacks S (2018) Collectin-11 (CL-
11) Is a Major Sentinel at Epi[INVESTIGATOR_745041]-Mediated Ischaemic Injury. Front. Immunol. 9:2023. doi: 10.3389/fimmu.2018.[ZIP_CODE]  
CONFIDENTIAL     C1INH (BerinertÂ®) IRI Study in Kidney Transplant  
	


27. Weiju Wu, Chengfei Liu, Conrad A. Farrar, Liang Ma, Xia Dong, Steven 
H. Sacks, Ke Li, Wuding Zhou. Collectin-11 Promotes the Development of Renal 
Tubulointerstitial Fibrosis. JASN Jan 2018, 29 (1) 168-
181; DOI: 10.1681/ASN.[PHONE_15554]  
28. Dalle Lucca JJ, Li Y, Simovic M, Pusateri AE, Falabella M, Dubick MA, Tsokos GC 
Effects of C1 inhibitor on tissue damage in a porcine model of controlled 
hemorrhage. Shock. 2012 Jul;38(1):82-91. 
 29. Castellano G, Melchiorre R, Loverre A, Ditonno P, Montinaro V,Rossini M, Divella C, Battaglia M, Lucarelli G, Annunziata G, Palazzo S, Selvaggi FP, Staffieri F, Crovace A,Daha MR,Mannesse M, van Wetering S, Paolo Schena F, 
Grandaliano G: Therapeutic targeting of classical and lectin pathways of complement 
protects from ischemia-reperfusion-induced renal damage. Am J Pathol 176: 1648â€“1659, 2010  
30. Heydenreich N et al. C1-Inhibitor Protects From Brain Ischemia-Reperfusion 
Injury by [CONTACT_745075]. 2012 
Sep;43(9):2457-67. 
 31. Edmund Huang,  Ashley Vo,  Jua Choi,  Noriko Ammerman,  Kathlyn Lim ,  Supreet Sethi,  Irene Kim,  Sanjeev Kumar,  Reiad Najjar,  Alice Peng,  and Stanley C. 
Jordan. Three-Year Outcomes of a Randomized, Double-Blind, Placebo-Controlled Study 
Assessing Safety and Efficacy of C1 Esterase Inhibitor for Prevention of Delayed Graft Function in Deceased Donor Kidney Transplant Recipi[INVESTIGATOR_745042]. J. Am Soc Nephrol. (in press)
doi: https://doi.org/10.2215/CJN.04840419 
 
Cicardi M, Levy RJ, McNeil DL, Li HH, Sheffer AL, Campi[INVESTIGATOR_2394] M, Horn PT, 
 Pullman WE. Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med. 2010 Aug 5;363(6):523-31.  
33. Cicardi M, Banerji A, Bracho F, MalbrÃ¡n A, Rosenkranz B, Riedl M, Bork K, Lumry 
W, Aberer W, Bier H, Bas M, Greve J, Hoffmann TK, Farkas H, Reshef A, Ritchie B, Yang W, Grabbe J, Kivity S, Kreuz W, Levy RJ, Luger T, Obtulowicz K, Schmid-Grendelmeier P, Bull C, Sitkauskiene B, Smith WB, Toubi E, Werner S, AnnÃ© S, BjÃ¶rkander J, Bouillet L, Cillari E, Hurewitz D, Jacobson KW, Katelaris CH, Maurer 
M, Merk H, Bernstein JA, Feighery C, Floccard B, Gleich G, HÃ©bert J, Kaatz M, Keith 
P, Kirkpatrick CH, Langton D, Martin L, Pi[INVESTIGATOR_1509] C, Resnick D, Wombolt D, FernÃ¡ndez Romero DS, Zanichelli A, Arcoleo F, Knolle J, Kravec I, Dong L, Zimmermann J, Rosen K, Fan WT. N Engl J Med. 2010 Aug 5;363(6):532-41. Erratum in: N Engl J Med. [ADDRESS_1019098] 7;363(15):1486. 
 
34. Vinci G, Lynch NJ, Duponchel C, Lebastard TM, Milon G Stover C, Schwaeble W, Tosi M. In Vivo Biosynthesis of Endogenous and of Human C1 Inhibitor in Transgenic Mice: Tissue Distribution and Colocalization of Their Expression. J Immunol 2002;169;5948-5954.  
 
35. Gandhi P, Gentry W, Bottorff M. Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: Investigation from the [LOCATION_002] Food & Drug Administration Adverse Events Reporting System. Pharmacotherapy 2012;32:902-909. 
 
CONFIDENTIAL     C1INH (BerinertÂ®) IRI Study in Kidney Transplant  
	


 
9Appendices 
Appendix A 



























	"  
 !  
" 




 	
 

 



 

 
	


"
#

#
+&

%+&
'$

*&
%"+'


)"+
%"

#("+
%"


$%(#%$)$*        

$"+)%$3."+)%$(*(        
$%#0*%$        
"	)*%(/        
%#&"*/)".#        
*")$)3-*        
9:4"       
)*4(/        
*/"%(*%(/*)*)516      
%(11

       
,-	)*%("(%"%)%(	
1
	1	1  
   
%(($$/*)*5%(6       
%(1($+*&+*
)+(#$*  
    
)*#*5'+*%$6        
#&*3/#%"%+"$        
,-$+#%%"$*%$        
($(*7,)"%
$+)%$       
	&($$
%(#""$       
2/*%!$)      
($(/
9;      
"/))))))#$*     .   
%$%#*$*#*%$)        
,(),$*%$*%($        
+* *%$))))#$*        
%$%()&$*%/        
))))%&)/        
CONFIDENTIAL     C1INH (BerinertÂ®) IRI Study in Kidney Transplant  
	


                 Appendix B 
CONFIDENTIAL     C1INH (BerinertÂ®) IRI Study in Kidney Transplant  
	


	

CONFIDENTIAL     C1INH (BerinertÂ®) IRI Study in Kidney Transplant  
	





CONFIDENTIAL     C1INH (BerinertÂ®) IRI Study in Kidney Transplant  
	


 
Appendix C 

CONFIDENTIAL     C1INH (BerinertÂ®) IRI Study in Kidney Transplant  
	


 
Appendix D 
 
 
Appendix E  
  
 
9.1Calculation of GFR from age, gender, race, urea, 
creatinine and albumin (MDRD equation) (Levey et al, 1999; Tattersall, 2003) 
Albumin in g/dL, age in years. GFR in mL/min/1.73 m
2.  
 
Multiply by 1.18 if patient is black. Multiply by 0.762 if 
patient is female. 
 
SI units (Creatinine in Î¼mol/L, Urea in mmol/L) 
GFR = 170 x (Creat x 0.0113)-0.999 x age-0.176 x (Urea x 2.8)-
0.17 x Alb0.318 
 
US units (Creatinine in mg/dL, BUN in mg/dL) 
GFR = 170 x Creat-0.999 x age-0.176 x BUN-0.17 x Alb0.318 
 
 


	




	



	



	

 	


	

 	
	



	


